Publications
Recent Articles and Reviews 2020
- Haiping Wang, Fabien Franco, Yao-Chen Tsui, Xin Xie, Marcel P. Trefny, Roberta Zappasodi, Syed Raza Mohmood, Juan Fernández-García, Chin-Hsien Tsai, Isabell Schulze, Florence Picard, Etienne Meylan, Roy Silverstein, Ira Goldberg, Sarah-Maria Fendt, Jedd D. Wolchok, Taha Merghoub, Camilla Jandus, Alfred Zippelius & Ping-Chih Ho. Nat Immunol (2020), doi: 10.1038/s41590-019-0589-5
- Trefny MP, Kaiser M, Stanczak MA, Herzig P, Savic S, Wiese M, Lardinois D, Läubli H, Uhlenbrock F, Zippelius A. PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunol Immunother. (2020),
doi: 10.1007/s00262-020-02558-z - Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse E, De Palma M, Zippelius A. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Proc Natl Acad Sci USA. (2020), doi: 10.1073/pnas.1902145116
Articles and Reviews 2019
- Kashyap A, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A. GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports, (2019), doi: 10.1016/j.celrep.2019.08.057
- Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse R, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Mohan P, Nicolini V, Birk M, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow C, Sai K, Caudell D, Burgos-Rodriguez A, Cline J, Hettich M, Ceppi M, Giusti A, Crameri F, Driessen W, Morcos P, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C and Umaña P. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine, (2019), doi: 10.1126/scitranslmed.aav5989
- Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. Journal for ImmunoTherapy of Cancer, (2019),
doi: 10.1186/s40425-019-0545-9 - Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clinical Cancer Research, (2019), doi: 10.1158/1078-0432.CCR-18-3041
- D’Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, Hell T, Wolter F, Beerli R, Truxova I, Špíšek R, Vlajnic T, Grawunder U, Reddy S, Zippelius A. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
doi: 10.1186/s40425-018-0464-1
Articles and Reviews 2018
- Pearce OMT, Läubli H. Cancer Immunotherapy. Glycobiology, (2018), doi: 10.1093/glycob/cwy069
doi: 10.1093/glycob/cwy069 - Ortega Sanchez G, Jahn K, Savic S, Zippelius A, Läubli H. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. J Immunother Cancer, (2018), doi: 10.1186/s40425-018-0400-4
doi: 10.1186/s40425-018-0400-4 - Läubli H, Dirnhofer S, Zippelius A. Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Arch, (2018), doi: 10.1007/s00428-018-2435-9
doi:10.1007/s00428-018-2435-9 - Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon MS, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest, (2018), doi: 10.1172/JCI120612
doi: 10.1172/JCI120612 - Heinz Läubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli and Sacha I. Rothschild. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. Journal for ImmunoTherapy of Cancer, (2018), doi.org/10.1186/s40425-018-0353-7
doi.org/10.1186/s40425-018-0353-7 - Daniela S. Thommen, Viktor H. Koelzer Petra Herzig, Andreas Roller, Marcel Trefny, Sarah Dimeloe, Anna Kiialainen, Jonathan Hanhart, Catherine Schill, Christoph Hess, Spasenija Savic Prince, Mark Wiese, Didier Lardinois, Ping-Chih Ho, Christian Klein, Vaios Karanikas, Kirsten D. Mertz, Ton N. Schumacher and Alfred Zippelius. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, (2018), doi: 10.1038/s41591-018-0057-z
doi.org/10.1038/s41591-018-0057-z - Berline Murekatete, Ali Shokoohmand, Jacqui McGovern, Lipsa Mohanty, Christoph Meinert, Brett G. Hollier, Alfred Zippelius, Zee Upton & Abhishek S. Kashyap. Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. Scientific Reports, (2018) 8:583 | doi:10.1038/s41598-017-19073-4
- Heinz Läubli, Philipp Müller, Lucia D’Amico, Mélanie Buchi, Abhishek S. Kashyap, Alfred Zippelius. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, (2018) doi.org/10.1007/s00262-018-2136-x https://link.springer.com/article/10.1007%2Fs00262-018-2136-x
Articles and Reviews 2017
- Olivia Joan Adams, Michal A Stanczak, Stephan von Gunten, Heinz Läubli. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology, 2017cwx108, doi.org/10.1093/glycob/cwx108
- Heinz Läubli, Viktor H. Koelzer, Matthias S. Matter, Petra Herzig, Béatrice Dolder Schlienger, Mark Nikolaj Wiese, Didier Lardinois, Kirsten D. Mertz & Alfred Zippelius. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. OncoImmunology. 2017 Oct 04. doi: 10.1080/2162402X.2017.1386362
- Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J Immunother Cancer. 2017 Jun 20;5:46. doi: 10.1186/s40425-017-0249-y.
- Prêtre V, Wicki A. Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy? Semin Cancer Biol. 2017 May 1. pii: S1044-579X(17)30107-4. doi: 10.1016/j.semcancer.2017.04.011.
- Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget. 2017 May 25. doi: 10.18632/oncotarget.18213
- Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Müller P, Kreuzaler M, Lu M, Favre S, Kreppel F, Löhning M, Luther SA, Zippelius A, Merkler D, Pinschewer DD. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nat Commun. 2017 May 26;8:15327. doi: 10.1038/ncomms15327
- Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD. [The pathology of adverse events with immune checkpoint inhibitors]. Pathologe. 2017 May;38(3):197-208. doi: 10.1007/s00292-017-0281-1
- Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007.
Articles and Reviews 2016
- Christian Ruiz, Stefan Kustermann, Elina Pietilae, Tatjana Vlajnic, Betty Baschiera, Leila Arabi, Thomas Lorber, Martin Oeggerli, Spasenija Savic, Ellen Obermann, Thomas Singer, Sacha I. Rothschild, Alfred Zippelius, Adrian B. Roth, Lukas Bubendorf Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine PLoS One. 2016; 11(8): e0160807. Published online 2016 Aug 22. doi: 10.1371/journal.pone.0160807
- Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. Mertz Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy J Immunother Cancer. 2016; 4: 47. Published online 2016 Aug 16. doi: 10.1186/s40425-016-0151-z
- Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May.
- Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res. 2016 Sep 2;4(9):744-54. doi: 10.1158/2326-6066.CIR-15-0156. Epub 2016 Jul 27.
- D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Carbonare LD, Godio L, Comoglio P, Trusolino L, Ferracini R, Roato I. C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget. 2016 Jun 14. doi: 10.18632/oncotarget.9997
- Kashyap AS, Shooter GK, Shokoohmand A2, McGovern J, Sivaramakrishnan M, Croll TI, Cane G, Leavesley DI, Söderberg O, Upton Z, Hollier BG. Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I-Induced Breast Cancer Cell Functions. Mol Cancer Ther. 2016 Jul;15(7):1602-13. doi: 10.1158/1535-7163.MCT-15-0907. Epub 2016 May 9.
- Pearce OM, Läubli H. Sialic acids in cancer biology and immunity. Glycobiology. 2016 Feb; 26(2): 111-28.
- Müller P, Rothschild SI, Arnold W, Hirschmann P, Horvath L, Bubendorf L, Savic S, Zippelius A. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother. 2016 Jan;65(1):1-11.
Articles and Reviews 2015
- Müller P, Kreuzalter M, Khan T, Thommen D, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTA-4/PD-1 blockade. Science Translational Medicine 25 Nov 2105
- Läubli H, Tzankov A, Juskevicius D, Degen L, Rochlitz C, Stenner-Liewen F. Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder. Leuk Lymphoma, 2015 Oct 8:1-4.
- Martins K, Schreiner J, Zippelius A. Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. http://www.ncbi.nlm.nih.gov/pubmed/26483791Front Immunol. 2015 Sep 29;6:501. doi: 10.3389/fimmu.2015.00501. eCollection 2015. Review
- Thommen DS, Schreiner J, Mueller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, Fischer OS, Moersig W, Savic Prince S, Levitsky V, Karanikas V, Lardinois D, Zippelius A. Progression of lung cancer is associated with increased dysfunction of T cells defined by co-expression of multiple inhibitory receptors. Cancer Immunol Res. 2015 Aug 7. pii: canimm.0097.2015
- Orleth A, Mamot C, Rochlitz C, Ritschard R, Alitalo K, Christofori G, Wicki A. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. J Drug Target. 2015 Jul 23:1-10.
- Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA. Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. J Natl Cancer Inst. 2015 Jun 11;107(7). pii: djv171. doi: 10.1093/jnci/djv171.
- Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015 Apr 21;3:11. doi: 10.1186/s40425-015-0057-1.
- Wieckowski S, Hemmerle T, Prince SS, Schlienger BD, Hillinger S, Neri D, Zippelius A. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. Lung Cancer. 2015 Apr;88(1):9-15. doi: 10.1016/j.lungcan.2015.01.019.
- Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C. Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial. Int J Pharm. 2015 Apr 30;484(1-2):8-15.
- Uda NR, Seibert V, Stenner-Liewen F, Müller P, Herzig P, Gondi G, Zeidler R, van Dijk M, Zippelius A, Renner C. Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity. J Enzyme Inhib Med Chem. 2015 Mar 16:1-6.
- Zippelius A, Schreiner J, Herzig P, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015 Mar;3(3):236-44. doi: 10.1158/2326-6066.CIR-14-0226.
- Rothschild SI, Thommen DS, Moersig W, Müller P, Zippelius A. Cancer immunology - development of novel anti-cancer therapies. Swiss Med Wkly. 2015 Feb 4;145:w14066. doi: 10.4414/smw.2015.14066.
- Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015 Feb 28;200:138-57. REVIEW
Articles and Reviews 2014
- Läubli H, Alisson-Silva F, Stanczak MA, Siddigui SS, Deng L, Verhagen A, Varki N, Varki A. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 2014 Nov 28;289(48):33481-91.
- Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.
- Läubli H, Pearce OM, Schwarz F, Siddigui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci USA, 2014 Sep 30; 111(39):14211-6.
- Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother. 2014 Sep;63(9):925-38. doi: 10.1007/s00262-014-1565-4.
- Müller P, Martin K, Theurich S, von Bergwelt-Baildon M, Zippelius A. Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. http://www.ncbi.nlm.nih.gov/pubmed/25610745Oncoimmunology. 2014 Aug 3;3(8):e954460.
- Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198.
- Tse BW1, Collins A, Oehler MK, Zippelius A, Heinzelmann-Schwarz VA.Antibody-based immunotherapy for ovarian cancer: where are we at? Ann Oncol. 2014 Feb;25(2):322-31. doi: 10.1093/annonc/mdt405.